News | January 18, 2023
Cipla launches Cippoint
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The company will respond to these observations within the stipulated time period.
The hospital will have all the modern facilities like modular OT, state of the art medical equipment, labs, etc. It will have OPD and IPD services
Subscribe To Our Newsletter & Stay Updated
